Three-year observational study on the long-term efficacy and safety of dupilumab in elderly patients with severe atopic dermatitis
The safety of dupilumab in older adults is crucial due to comorbidities and polypharmacy, but this group is often underrepresented in clinical trials. We herein report a real-world experience with dupilumab in treating 138 atopic dermatitis in patients aged 60 years and older. Our study demonstrated that dupilumab has excellent safety outcomes and consistent improvements across all clinical scores.
Authors
- Armando Pisapia (ORCID: https://orcid.org/0000-0002-7326-3253)
- Angelo Valerio Marzano (ORCID: https://orcid.org/0000-0002-8160-4169)
- Paolo Calzari (ORCID: https://orcid.org/0000-0001-7690-7221)
- Alessandra Chiei Gallo (ORCID: https://orcid.org/0000-0001-8028-5453)
- Silvia Mariel Ferrucci (ORCID: https://orcid.org/0000-0002-6734-1366)
- Francesca Barei (ORCID: https://orcid.org/0000-0002-7188-7310)
Institutions
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1093/ced/llae420
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.53